DORIPENEM HYDRATE ( DrugBank: Doripenem )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-001225-16-Outside-EU/EEA
(EUCTR)
24/04/2015A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic FibrosisAn Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Subjects 6 to 17 Years of age, Inclusive, With Cystic Fibrosis Cystic fibrosis
MedDRA version: 18.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: DORIBAX
Product Name: DORIBAX
INN or Proposed INN: DORIPENEM HYDRATE
Other descriptive name: DORIPENEM HYDRATE
Johnson & Johnson Pharmaceutical Research & Development L.L.CNULLNAFemale: yes
Male: yes
22United States